Santis Health

santishealth.ca

Santis Health is a consultancy dedicated to providing value-added strategic advisory services to clients within the Canadian health care sector. Santis navigates the intersection of public policy, advocacy, and communications. Our services include strategic planning, policy analysis and development, public affairs, and communications. Clients of Santis Health include leading health care organizations, charities, non-profits, and health care providers across Canada. We pride ourselves on understanding the system dynamics that drive policy making, resource allocation, and stakeholder opinion.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT, INDUSTRY OUTLOOK

PUMA BIOTECHNOLOGY REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

Puma Biotechnology | December 06, 2022

news image

Puma Biotechnology, Inc. a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employe...

Read More

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

news image

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More

CELL AND GENE THERAPY

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

news image

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

news image

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More
news image

INDUSTRIAL IMPACT, INDUSTRY OUTLOOK

PUMA BIOTECHNOLOGY REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

Puma Biotechnology | December 06, 2022

Puma Biotechnology, Inc. a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 20,625 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employe...

Read More
news image

GENETIC TESTING MARKET TO SET NEW GROWTH STORY: TRANSGENOMIC, GE HEALTHCARE, 23 & ME

EIN News | April 16, 2020

Advance Market Analytics released the research report of Global Genetic Testing Market, offers a detailed overview of the factors influencing the global business scope. Global Genetic Testing Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Genetic Testing. This Report covers the emerging player’s data, including: competit...

Read More
news image

CELL AND GENE THERAPY

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More
news image

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More